Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised IBT on its Nasdaq Stockholm main market listing
Mandate

Vinge advised IBT on its Nasdaq Stockholm main market listing

September 10, 2018 Capital Markets and Public M&A

The shares of Infant Bacterial Therapeutics AB (publ) have been admitted to trading on the main market of Nasdaq Stockholm (Mid Cap).

 Vinge advised IBT.

The Vinge team included Erik Sjöman, Christian Lindhé and Astrid Karlsson..
 

Related

Vinge has advised Oncopeptides in connection with a directed share issue

 Vinge has advised Oncopeptides in connection with a directed share issue, whereby Oncopeptides raises proceeds of SEK 100 million.
October 16, 2026

Vinge advises KGAL on its divestment of a Nordic wind portfolio to Enordic Evergreen

 Vinge has advised KGAL on the divestment of a Nordic onshore wind portfolio to Enordic Evergreen.
October 14, 2026

Vinge has advised Orexo in connection with its rights issue

 Vinge has advised Orexo AB (publ) in connection with a partially guaranteed rights issue of approximately SEK 250 million before transaction costs, subject to approval by an extraordinary general meeting.
October 09, 2026